Unruptured Cerebral Aneurysm Screening: Who, When, and How
Executive Summary
Unruptured intracranial aneurysms (UIA) are present in roughly 3% of the adult population, yet only a small minority warrant detection because most pose minimal lifetime rupture risk and screening can lead to invasive treatment with its own morbidity. The clinical task is therefore not "screen everyone" but to identify the narrow population in whom a positive scan changes management — patients with ≥2 first-degree relatives with subarachnoid hemorrhage (SAH) or known UIA, autosomal dominant polycystic kidney disease (ADPKD) with affected family members, and a handful of connective-tissue or vascular syndromes (Ehlers-Danlos type IV, Loeys-Dietz, fibromuscular dysplasia, coarctation of the aorta).
The preferred modality is 3D time-of-flight MRA at 3 Tesla without gadolinium, which detects ≥3 mm aneurysms with sensitivity 93–95% and avoids contrast and ionizing radiation. CTA is an acceptable alternative when MRA is unavailable; DSA is reserved for definitive characterization or treatment planning. When an UIA is found, the PHASES score (Population, Hypertension, Age, Size, Earlier SAH, Site) and ISUIA size-and-location data drive treatment decisions: anterior circulation aneurysms ≥7 mm and posterior circulation aneurysms ≥5 mm are generally offered repair, smaller lesions are followed with serial imaging at 1, 3, and 5 years. Treatment is now endovascular-first for most lesions (coiling, flow diversion, or WEB device), with microsurgical clipping reserved for wide-necked MCA bifurcation aneurysms and selected anterior communicating lesions.
S1 · Epidemiology & Rupture Risk Stratification
Rupture risk granularity beyond size alone: The often-quoted "1% annual rupture risk" is a population average that obscures wide variation. ISUIA stratification produced markedly different annual rupture rates depending on size and location — anterior circulation aneurysms <7 mm had effectively negligible 5-year rupture rates in untreated patients without prior SAH, while posterior communicating and posterior circulation lesions had substantial risk even at small size. PHASES integrates Population (Japanese/Finnish higher), Hypertension, Age >70, Size, Earlier SAH, and Site to give a 5-year cumulative rupture probability ranging from <1% to >15%. Modern practice increasingly adds morphologic features (lobulation, daughter sac, aspect ratio >1.6, size ratio >3) and serial-imaging growth (any documented growth in a 12-month interval increases rupture risk roughly 9-fold) to the size-and-location framework. The single highest-yield variable in experienced practice is documented growth — a stable 5-mm lesion at 3 years behaves very differently from a 5-mm lesion that grew from 3 mm in the prior year.
Unruptured intracranial aneurysms are a common incidental finding. A 2011 meta-analysis (Vlak et al., Lancet Neurology) of 94 studies found a prevalence of 3.2% in adults without comorbidity, rising to ~6% in those with autosomal dominant polycystic kidney disease and ~10% in adults with ≥1 affected first-degree relative. The female-to-male ratio is approximately 2:1, peaks in the sixth decade, and Japanese and Finnish populations carry roughly twice the global average prevalence — both genetic background and shared environmental factors contribute.
Why most aneurysms never rupture
The annual rupture rate for an asymptomatic UIA <7 mm in the anterior circulation, in a patient without prior SAH, is approximately 0–0.5% per year. The PHASES study cohort confirmed that small (<7 mm), anteriorly located, low-risk aneurysms have a 5-year cumulative rupture risk under 1%, whereas a 13–24 mm posterior circulation aneurysm in a hypertensive 70-year-old Japanese patient with prior SAH carries a 5-year risk approaching 15%. Risk stratification is therefore essential before any treatment decision.
Modifiable risk factors
Counsel every patient with an UIA on tight blood pressure control (target SBP <130 mmHg), tobacco cessation (smoking doubles rupture risk and triples growth rate), and moderation of alcohol intake (>150 g/week increases risk). Stimulant drug use (cocaine, amphetamines) and uncontrolled hypertensive crises are catastrophic precipitants. Aspirin 81 mg daily — historically feared as a hemorrhage promoter — has accumulated observational data (ISUIA, IRAS) suggesting reduced rupture risk through anti-inflammatory effects on aneurysm wall, though guidelines do not yet endorse it for primary prevention.
| Risk factor | Annual rupture rate adjustment | Modifiable? |
|---|---|---|
| Anterior circulation, <7 mm, no prior SAH | 0–0.5%/year baseline | — |
| Hypertension uncontrolled (SBP >160) | ×1.4 | ✓ Tight BP <130 |
| Active smoking (current) | ×2.2 | ✓ Cessation |
| Posterior circulation location | ×4.0 | ✗ |
| Size ≥10 mm | ×6.5 (vs <7 mm) | ✗ |
| Prior SAH from another aneurysm | ×3.5 | ✗ |
| Female sex | ×1.6 | ✗ |
| Japanese/Finnish ancestry | ×2.8 | ✗ |
S2 · Who to Screen — Indication-Driven Approach
Population-based screening of asymptomatic adults is not recommended. Cost-effectiveness analyses (Bor et al. 2014, Stroke) demonstrate that even at a 3% prevalence, mass screening would detect many small aneurysms that pose lower lifetime risk than the morbidity of treatment, and would generate substantial harm from invasive workup and "incidentaloma anxiety." Screening is reserved for groups with relative risk ≥4× and a probability of detection that justifies the cost and downstream cascade.
Familial intracranial aneurysm (FIA)
The strongest indication. The lifetime risk of harboring an aneurysm rises from ~3% in the general population to ~10% with one first-degree relative with SAH or known UIA, and to ~20% with two or more first-degree relatives. AHA/ASA 2015 and ESO 2022 guidelines recommend non-invasive screening only when ≥2 first-degree relatives are affected. Screening one relative with one affected family member yields too low a pretest probability to justify the workup cascade.
Autosomal dominant polycystic kidney disease (ADPKD)
UIA prevalence in ADPKD is roughly 6–9%, rising to 16–22% if there is a family history of SAH or aneurysm within the ADPKD pedigree. Screen ADPKD patients only when (1) family history of SAH or UIA in another ADPKD-affected relative, OR (2) the patient has high-risk occupation (pilot, diver, scuba), or (3) prior to renal transplant evaluation. Routine screening of all ADPKD patients without these features is not justified.
Genetic and connective-tissue syndromes
| Condition | UIA risk | Screen? |
|---|---|---|
| ≥2 first-degree relatives with SAH/UIA | ~20% lifetime | YES — MRA at age 25 |
| 1 first-degree relative with SAH/UIA | ~10% lifetime | Individualized; usually NO |
| ADPKD with family history of UIA/SAH | 16–22% | YES — MRA at diagnosis |
| ADPKD without family history | 6–9% | NO routinely; high-risk job → consider |
| Ehlers-Danlos type IV (vascular) | ~12% | YES — and avoid catheter angio |
| Loeys-Dietz syndrome | ~10% | YES at diagnosis |
| Fibromuscular dysplasia (renal/carotid) | ~7% | YES — one-time MRA |
| Coarctation of the aorta | ~10% | YES — one-time MRA |
| α1-antitrypsin deficiency | 3–5× | Individualized |
| Sickle cell disease (adult) | ~10% | YES if prior stroke or moyamoya |
| Smoker, hypertensive, no family history | ~3–4% | NO |
S3 · Imaging Modality — MRA, CTA, or DSA?
Three modalities image the cerebral arterial tree, each with a distinct profile of accuracy, safety, and downstream consequence. For screening (asymptomatic patients with risk factors but no neurologic deficit), the goal is high sensitivity for clinically actionable aneurysms (≥3–5 mm) while avoiding ionizing radiation, contrast, and arterial puncture.
3D time-of-flight MRA (TOF-MRA) — first-line for screening
3T TOF-MRA without gadolinium achieves sensitivity 93–95% and specificity 96–98% for aneurysms ≥3 mm, dropping to ~80% for aneurysms 1–3 mm. It avoids ionizing radiation entirely and does not require IV contrast in routine screening protocols. 3T MRA · TOF, no contrast Acquisition time is 10–15 minutes; thin-slice reconstruction (0.5–1 mm) and maximum-intensity projection (MIP) post-processing are essential. Limitations: motion artifact in restless patients, signal loss in slow-flow giant aneurysms (paradoxical "false negative"), and venous contamination near the cavernous sinus.
CTA — second-line
CT angiography with iodinated contrast is sensitivity 95–98% and specificity 95% for aneurysms ≥3 mm, faster (5 min acquisition), and offers superior bony detail useful for surgical planning. Drawbacks: ionizing radiation (effective dose ~3 mSv to head, with lens dose a particular concern in young patients), contrast nephropathy risk, and beam-hardening artifact at the skull base may obscure paraophthalmic aneurysms. Use CTA when MRA is contraindicated (pacemaker, severe claustrophobia) or when bony anatomy guides surgery.
Digital subtraction angiography (DSA) — gold standard, but invasive
DSA remains the reference standard with sensitivity ~98% and the only modality offering rotational 3D reconstruction for definitive characterization of neck morphology, daughter sacs, and parent vessel involvement. It is not used for screening due to a 0.3–0.5% risk of stroke or transient neurological deficit and 0.05% risk of permanent neurological deficit (CATCH study, AVERT registry). Reserve DSA for: positive screening MRA/CTA where treatment is being planned, lesions of indeterminate morphology, suspected pseudoaneurysm or arteriovenous malformation co-pathology.
| Modality | Sensitivity (≥3 mm) | Radiation | Contrast | Procedural risk | Use case |
|---|---|---|---|---|---|
| 3T TOF-MRA | 93–95% | None | None routine | 0% | Primary screening |
| CTA | 95–98% | ~3 mSv | Iodinated | ~0.1% nephropathy | MRA contraindicated; surgical planning |
| DSA | ~98% | 5–7 mSv | Iodinated | 0.3–0.5% TIA, 0.05% stroke | Treatment planning only |
S4 · Screening Intervals & Surveillance
Initial screen — when to start
For familial intracranial aneurysm (≥2 first-degree relatives with SAH/UIA), AHA/ASA 2015 recommends initial MRA at age 25, or 5–10 years before the youngest age of SAH in any affected family member, whichever is earlier. For ADPKD with family history, screen at the time of ADPKD diagnosis or at age 18 if diagnosed earlier. For Ehlers-Danlos type IV, Loeys-Dietz, fibromuscular dysplasia, and coarctation, perform a one-time screening MRA at the time of underlying diagnosis.
Negative screen — rescreening interval
A negative screen does not eliminate lifetime risk because aneurysms develop progressively. Recommended intervals (AHA/ASA 2015, ESO 2022):
- FIA, normal initial MRA: rescreen every 5 years until age 70 (de novo aneurysm rate ~2.4% over 10 years in this group)
- ADPKD, normal initial MRA: rescreen every 5–10 years; sooner (every 3–5 years) if hypertensive or smoker
- Ehlers-Danlos, Loeys-Dietz: rescreen every 2–3 years given accelerated vascular pathology
- One-time syndromes (FMD, coarctation): repeat only if new neurologic symptoms develop
Positive screen — surveillance schedule for untreated UIA
When a small aneurysm (<7 mm anterior, <5 mm posterior) is found and not treated, surveillance MRA is performed at 6–12 months, then annually for 2–3 years, then every 2–3 years if stable. Aneurysm growth ≥1 mm in any dimension is the principal indication to convert to treatment regardless of absolute size, because growth confers a 12-fold increase in 5-year rupture risk (TEAM, ELAPSS data).
| Scenario | Initial screen | Rescreen interval (negative) | Surveillance (positive, untreated) |
|---|---|---|---|
| ≥2 first-degree relatives SAH/UIA | Age 25 or 5–10y before youngest family SAH | Every 5 years to age 70 | 6–12 mo → annually × 2–3y → q2–3y |
| ADPKD + family hx UIA/SAH | At ADPKD diagnosis (or age 18) | Every 5 years | 6–12 mo → q2–3y |
| ADPKD only (high-risk job) | One-time at diagnosis | Every 10 years | q2–3y |
| Ehlers-Danlos IV / Loeys-Dietz | At diagnosis | Every 2–3 years | q6–12 mo |
| Fibromuscular dysplasia | One-time | Only if symptomatic | q6–12 mo |
| Coarctation of aorta | One-time | Only if symptomatic | q6–12 mo |
S5 · Treatment Thresholds — PHASES & ISUIA
The PHASES score
The PHASES score (Greving et al. 2014, Lancet Neurology) pools 6 international cohorts (8,382 patients, 17,545 person-years) into a 5-year rupture risk calculator. The acronym: Population, Hypertension, Age, Size of aneurysm, Earlier SAH from another aneurysm, Site of aneurysm.
| Variable | Categories | Points |
|---|---|---|
| Population | North American/European (non-Finnish) / Japanese / Finnish | 0 / 3 / 5 |
| Hypertension | No / Yes | 0 / 1 |
| Age | <70 / ≥70 years | 0 / 1 |
| Size (mm) | <7 / 7.0–9.9 / 10–19.9 / ≥20 | 0 / 3 / 6 / 10 |
| Earlier SAH | No / Yes | 0 / 1 |
| Site | ICA / MCA / ACA-Pcom-posterior | 0 / 2 / 4 |
Total ranges 0–22, mapping to 5-year rupture risk:
- 0–2 points: 0.4% (treat conservatively, surveillance)
- 3–4 points: 1.3%
- 5–6 points: 3.2% (consider treatment if patient <65 and life expectancy >10 years)
- 7–8 points: 5.3% (treatment generally favored)
- 9–10 points: 8.4%
- ≥11 points: 17.8% (treat unless prohibitive comorbidity)
ISUIA-derived size thresholds
The International Study of Unruptured Intracranial Aneurysms (ISUIA) prospective cohort (Wiebers 2003, Lancet) established the still-cited size thresholds:
| Location | <7 mm | 7–12 mm | 13–24 mm | ≥25 mm |
|---|---|---|---|---|
| Anterior circulation, no prior SAH | 0% / 5y | 2.6% | 14.5% | 40% |
| Anterior circulation, prior SAH | 1.5% | 2.6% | 14.5% | 40% |
| Posterior circulation (incl. Pcom) | 2.5% | 14.5% | 18.4% | 50% |
Decision rule synthesis
In practice, neurosurgeons combine PHASES, ISUIA, and patient-specific factors (life expectancy, treatment preference, occupational risk) into a shared decision. A reasonable framework:
- Treat: Anterior aneurysm ≥7 mm, posterior aneurysm ≥5 mm, any symptomatic lesion, growth ≥1 mm, irregular morphology, PHASES ≥7, prior SAH from another aneurysm
- Discuss carefully: Anterior 5–7 mm in young patient (life expectancy >20 years), PHASES 5–6 in healthy patient under 65
- Surveillance: Anterior <5 mm regular morphology in patient ≥70 with comorbidities, PHASES ≤4
S6 · Treatment Options & Frequently Asked Questions
Endovascular vs microsurgical clipping
The ISAT trial (2002, ruptured aneurysms) established endovascular coiling as superior to clipping for poor-grade SAH patients. For unruptured aneurysms, the BRAT trial and CARAT registry suggest broadly equivalent durability with lower upfront morbidity for coiling. Modern practice is endovascular-first for most lesions:
- Simple coiling — narrow-neck saccular aneurysms, dome-to-neck ratio ≥2; primary occlusion 70–85%, retreatment rate 8–10% at 5 years
- Stent-assisted coiling — wide-neck aneurysms; requires dual antiplatelet therapy (aspirin 81 mg + clopidogrel 75 mg) for 3–6 months
- Flow diversion (Pipeline embolization device, Surpass) — large/giant ICA aneurysms, proximal-segment lesions; complete occlusion at 1 year ~85%, progressive remodeling over months; requires dual antiplatelet therapy 6+ months
- Intrasaccular flow disruption (WEB device) — wide-neck bifurcation aneurysms (basilar tip, MCA), avoids stent and dual antiplatelet
- Microsurgical clipping — wide-necked MCA bifurcation aneurysms with branch involvement, anterior communicating aneurysms in young patients (durability advantage), failed coil/recurrent lesions
Periprocedural risk by treatment
| Treatment | Mortality | Stroke/permanent deficit | Re-treatment at 5y |
|---|---|---|---|
| Coiling (simple) | 0.5–1% | 3–5% | 8–10% |
| Stent-assisted coiling | 1–1.5% | 5–7% | 5–7% |
| Flow diversion | 1–2% | 5–8% | 3–5% |
| WEB device | 0.5–1% | 3–4% | 10–12% (newer device) |
| Microsurgical clipping | 1–2% | 6–10% | 1–2% (most durable) |
FAQ
S7. Practice Insights: Aneurysm Screening Without Causing Harm
1. Screen Only with Strong Indications
In practice, experienced clinicians screen only the following: two or more first-degree relatives with SAH or intracranial aneurysm, ADPKD with family history of SAH (or any ADPKD aged 30-65 considered for renal transplant), connective tissue disorders (Loeys-Dietz, vascular Ehlers-Danlos, Marfan), prior SAH that has been treated (to look for de-novo aneurysms), coarctation of the aorta or fibromuscular dysplasia, and prior intracranial arterial dissection. Seasoned clinicians do NOT screen incidental smokers, hypertensives, or anxious patients without these indications. Population screening for cerebral aneurysms is not supported by evidence and produces net harm from the anxiety and surveillance burden of low-risk incidentalomas.
2. Pre-Test Counseling Is Mandatory
Before clinicians order any aneurysm screening MRA, experienced practitioners sit with the patient for a focused 10-15 minute conversation. They tell them: the test will likely be normal, but if an aneurysm is found they will need to decide between surveillance imaging every 6-12 months indefinitely OR treatment with endovascular coiling or surgical clipping, each carrying about 5-10% serious complication risk. Experienced clinicians tell them that small (<5 mm) anterior-circulation aneurysms in non-Japanese non-smokers have rupture rates below the annual risk of treatment complications, so they may end up just watching. About 1 in 10 patients clinicians counsel pre-test decline screening after this conversation — which is a perfectly acceptable outcome.
3. MRA over CTA for Screening
For screening (not for acute SAH workup or treatment planning), 3T time-of-flight MRA is the first-line modality. No ionizing radiation matters when patients may need 15-20 repeat scans over a lifetime. No iodinated contrast matters in ADPKD patients with declining renal function. MRA has sensitivity around 95% for aneurysms 3 mm or larger, which is the clinically meaningful threshold. clinicians reserve CTA for patients with MRI contraindications (pacemakers, claustrophobia, severe motion artifact) and DSA only for surgical/endovascular planning or characterization of ambiguous lesions where MRA and CTA disagree.
4. Growth Trumps Size at Surveillance
In experienced hands, the single most important variable on serial imaging is documented growth, not absolute size. A stable 5-mm aneurysm at 3 years of surveillance has a roughly 0.5% annual rupture rate; a 5-mm aneurysm that grew from 3 mm in the prior year has 5-10x higher rupture risk. Seasoned clinicians now use comparison side-by-side review with the prior scan as a standing protocol — not just reading the new scan in isolation. Any documented growth >0.5 mm in the maximal dimension triggers re-evaluation for treatment, regardless of absolute size. New irregularity, lobulation, or daughter sac development also triggers re-evaluation independent of size change.
Illustrative Scenario: The Screening That Created Years of Anxiety
A woman in her late 40s was referred to the treating clinicians with a 2-year history of moderate anxiety and depression that began the day she was told she had a 3 mm right anterior cerebral artery aneurysm. The screening MRA had been ordered by her PCP because her father had died of SAH at age 72 — the only relevant family history. The patient had no other risk factors: never-smoker, normotensive, no connective tissue disorder, no ADPKD. Her PHASES score was 4 (driven entirely by anterior cerebral artery site = 4 points, with 0 for population, hypertension, age, size, and earlier SAH; the single first-degree relative is a screening-indication issue, not a PHASES input, and does not meet the 2+ threshold, so she should never have been screened).
On the evaluation the aneurysm had been stable across 4 surveillance MRA studies over 24 months. Annual rupture risk was <0.5%. Treatment risk for this location would have been 5-7% for coiling. The treating clinicians conveyed clearly that this was an extremely low-risk finding that did NOT warrant treatment, that surveillance intervals could safely lengthen to every 2 years, and that they would only re-evaluate if growth or new morphology emerged. They referred her to a psychologist for health-anxiety CBT and her PCP for SSRI titration. Her quality of life improved substantially over the following 12 months, but the underlying lesson is that the original screening should never have been ordered.
Practice Pattern Refinements vs Standard Approach
- Indication discipline: 2+ first-degree relatives, ADPKD with FH, connective tissue disorder, prior treated SAH, coarctation, FMD, prior dissection. Do NOT screen on incidental smoking or HTN alone.
- 10-15 minute pre-test counseling covering surveillance vs treatment risks. Roughly 10% decline after counseling, which is acceptable.
- 3T MRA first-line for screening. No radiation/contrast over a lifetime of surveillance. CTA only for MRI contraindications.
- Growth trumps size: any documented growth >0.5 mm or new morphology (lobulation, daughter sac) triggers re-evaluation regardless of absolute size. Side-by-side comparison review is mandatory.
- Brain AVM: Spetzler-Martin Grading, Hemorrhage Risk, and Treatment Decision-Making
- Migraine Prophylaxis: Beta-Blockers, Topiramate, CGRP Monoclonals, Gepants, and Botox for Chronic Migraine
- Acute Ischemic Stroke — Rapid Diagnosis and Treatment
- Idiopathic Intracranial Hypertension: Diagnosis and Management
- Trigeminal Neuralgia: Diagnosis and Management
- Huntington Disease: Diagnosis and Management